

3. The composition of claim 2, comprising lymphocytes from at least three different humans.
4. The composition of claim 3, comprising lymphocytes from at least four different humans.
5. The composition of claim 2, wherein lymphocytes from at least one of the humans is inactivated.

Amended
B3
C2
6. **(Amended)** A pharmaceutical composition suitable for administration to a human, comprising alloactivated lymphocytes and a tumor associated antigen in a compatible pharmaceutical excipient, wherein administration of the composition to a patient having a tumor elicits an immunological response by the patient against the tumor.

Amended
26. The composition of claim 6, which is formulated for subcutaneous or intramuscular administration, wherein administration of the composition at a site distal to the tumor elicits an immunological response by the patient against the tumor.

7. The composition of claim 6, wherein the tumor-associated antigen is expressed on a tumor cell present in the composition.

8. **(Amended)** The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with human cells *ex vivo* expressing HLA-DR antigens that are allogeneic to both HLA-DR antigens on the lymphocytes.

B3
Amended
C4
9. **(Amended)** The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* for a time whereby the lymphocytes become sufficiently alloactivated to be effective in eliciting an anti-tumor immunological response when administered to a human.

10. **(Amended)** The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* for a time whereby the lymphocytes become sufficiently alloactivated to be effective in extending life expectancy or causing progressive reduction in tumor mass when administered to a human having a tumor.

11. (Amended) The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* until about the time when secretion of IFN- γ by the alloactivated lymphocytes is highest.

12. (Amended) The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* until about the time when secretion of IL-2 by the alloactivated lymphocytes is highest.

13. (Amended) The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* for between about 12 hours and 5 days.

14. (Amended) The composition of claim 25, wherein the lymphocytes are alloactivated by coculturing with allogeneic human cells *ex vivo* for between about 24 and 72 hours.

15. A kit comprising components of the composition of claim 6 in separate containers.

16. (Amended) A device for treatment of a tumor in a human patient, containing the composition of claim 25.

17. The device of claim 16, which is an injection needle.

18. The device of claim 16, which is suitable for positioning by ultrasound guided endoscopy.

19. (Amended) A method for treating cancer in a human patient, comprising administering to the patient the pharmaceutical composition of claim 25.

20. (Amended) A method for eliciting an anti-tumor immunological response in a human patient, comprising administering to the patient the pharmaceutical composition of claim 25.

21. A method for treating cancer in a human patient, comprising administering to the patient the pharmaceutical composition of claim 6.

22. A method for eliciting an anti-tumor immunological response in a human patient, comprising administering to the patient the pharmaceutical composition of claim 6.
23. The method of claim 19, wherein the pharmaceutical composition is administered at or around the site of a solid tumor in the patient.
24. The method of claim 21, wherein the pharmaceutical composition is administered at a site distal to the tumor.